CLPT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
12.1M
+11.0%
10.9M
-10.3%
12.1M
+16.5%
10.4M
+17.5%
8.9M
Cost of Revenue
5.0M
+20.3%
4.2M
-4.6%
4.4M
+9.1%
4.0M
+22.8%
3.3M
Gross Profit
7.1M
+5.2%
6.7M
-13.5%
7.8M
+21.1%
6.4M
+14.4%
5.6M
Operating Expenses
13.4M
-21.0%
17.0M
+4.4%
16.2M
+20.7%
13.4M
+23.7%
10.9M
R&D
4.0M
-13.3%
4.6M
+2.4%
4.5M
+39.7%
3.2M
-6.2%
3.5M
SG&A
9.4M
-23.9%
12.3M
+5.2%
11.7M
+14.7%
10.2M
+37.6%
7.4M
Operating Income
-6332000
+38.2%
-10244000
-20.8%
-8478000
-20.3%
-7045000
-33.5%
-5276000
EBITDA
-4710000
+46.9%
-8870000
-20.4%
-7365000
-18.9%
-6194000
-27.7%
-4850000
Net Income
-7460000
+34.2%
-11337000
-18.7%
-9552000
-22.7%
-7786000
-32.2%
-5891000
EPS (Basic)
$-0.24
+36.8%
$-0.38
-18.8%
$-0.32
-18.5%
$-0.27
-28.6%
$-0.21
EPS (Diluted)
$-0.24
+36.8%
$-0.38
-18.8%
$-0.32
-18.5%
$-0.27
-28.6%
$-0.21
Shares (Diluted)
31.0M
+2.7%
30.2M
+2.1%
29.5M
+2.4%
28.9M
+1.5%
28.4M
ClearPoint Neuro (CLPT) — Financials